YHB Investment Advisors Inc. lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.2% during the second quarter, Holdings Channel reports. The fund owned 65,845 shares of the company’s stock after selling 154 shares during the period. Johnson & Johnson comprises 1.0% of YHB Investment Advisors Inc.’s holdings, making the stock its 23rd biggest holding. YHB Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $10,899,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. Independent Advisor Alliance grew its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock valued at $25,380,000 after buying an additional 1,327 shares during the last quarter. Peak Asset Management LLC grew its stake in shares of Johnson & Johnson by 9.3% during the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock valued at $2,137,000 after buying an additional 1,171 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.9% during the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after buying an additional 6,836 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in shares of Johnson & Johnson by 21.8% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after buying an additional 161,687 shares during the last quarter. Finally, Tekla Capital Management LLC grew its stake in shares of Johnson & Johnson by 12.8% during the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after buying an additional 82,100 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on JNJ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Friday. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 26th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday. Finally, HSBC initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 target price for the company. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $169.19.
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $149.91 on Tuesday. The company’s 50-day moving average price is $154.52 and its 200-day moving average price is $160.29. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $181.04. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The company has a market cap of $360.88 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The firm had revenue of $21.35 billion for the quarter, compared to the consensus estimate of $21 billion. On average, equities research analysts forecast that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, November 20th. This represents a $4.76 annualized dividend and a yield of 3.18%. Johnson & Johnson’s payout ratio is 35.34%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- Why Invest in 5G? How to Invest in 5G Stocks
- Safeguard your portfolio with these three bargain stocks
- How to Invest in Small Cap Stocks
- Membership clubs gain leverage for the consumer rebound
- What is an Earnings Surprise?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.